CIA
REGN icon

Caerus Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Caerus Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$841K Sell
1,349
-317
-19% -$216K 0.28% 65
2026
Q1 		$1.29M Buy
1,666
+27
+2% +$20.7K 0.54% 36
2025
Q4 		$1.27M Buy
1,639
+310
+23% +$211K 0.41% 45
2025
Q3 		$747K Buy
+1,329
New +$751K 0.31% 63

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Caerus Investment Advisors's REGN Position: Q2 2026 in Review

Caerus Investment Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $216K and leaving 1,349 shares worth $841K. The position accounts for 0.28% of the portfolio, ranked #65.

Caerus Investment Advisors first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.29M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Caerus Investment Advisors held 1,349 shares of Regeneron Pharmaceuticals worth $841K as of Q2 2026.
  • Caerus Investment Advisors sold 317 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
  • Regeneron Pharmaceuticals made up 0.28% of Caerus Investment Advisors's portfolio in Q2 2026, its #65 holding.
  • Caerus Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Caerus Investment Advisors's Regeneron Pharmaceuticals position peaked at $1.29M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Caerus Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.